The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback